We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High-Sensitivity Troponin Demonstrates Potential for Diagnosing Acute Coronary Syndrome

By LabMedica International staff writers
Posted on 24 Sep 2024

Chest pain is a common yet difficult symptom for general practitioners to assess, as it can stem from both serious and benign conditions. More...

Now, a new study has found that high-sensitivity troponin tests have the potential to diagnose acute coronary syndrome in primary care settings.

In the study, researchers at the Leiden University Medical Center (Leiden, The Netherlands) evaluated the effectiveness of various risk assessment tools, including clinical decision rules and troponin tests, in helping general practitioners rule out acute coronary syndrome in patients presenting with chest pain. They conducted a systematic review of studies involving adult patients with chest pain in primary care. The review included studies that assessed the diagnostic accuracy of different clinical decision rules and troponin point-of-care tests, both conventional and high-sensitivity, for identifying acute coronary syndrome, including heart attacks. These tools were compared to the unaided clinical judgment of general practitioners.

The review, which included 14 studies, revealed that some clinical decision rules without troponin improved safety. However, none consistently outperformed the unaided judgment of general practitioners in ruling out acute coronary syndrome. Conventional troponin tests, when used alone, did not meet the required diagnostic accuracy, making them less reliable in primary care. High-sensitivity troponin tests demonstrated the greatest diagnostic accuracy but require further prospective validation in primary care before being recommended for widespread use. While these tests show promise, they are not yet ready to replace clinical judgment or be used independently without additional validation.

Related Links:
Leiden University Medical Center


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.